{"id":"W4365512156","doi":"10.1158/1538-7445.am2023-ct149","title":"Abstract CT149: BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Translational Research in Oncology; Jewish General Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Hamilton Health Sciences; University of Alberta","funders":"","keywords":"FOLFOX; Medicine; Clinical endpoint; Internal medicine; Oncology; Interim analysis; Colorectal cancer; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; Oxaliplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001538685,0.001562286,0.001826037,0.0005789461,0.0004116895,0.001095643,0.001258045,0.001478018,0.006603996],"category_scores_gemma":[0.0007214964,0.0006067797,0.001202565,0.0005680053,0.0008585639,0.0007258882,0.0004134968,0.005211195,0.001548653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001173005,"about_ca_system_score_gemma":0.00200323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001245054,"about_ca_topic_score_gemma":0.002999721,"domain_scores_codex":[0.9995449,0.0002083981,0.00002952598,0.00006985204,0.00005889249,0.00008835988],"domain_scores_gemma":[0.9992238,0.00009160337,0.0001547752,0.00007254707,0.00005986392,0.0003973668],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5047567,0.1558537,0.006854079,0.0009974071,0.001551521,0.0005096663,0.0003216134,0.004412786,0.2097259,0.0006082436,0.01316795,0.1012405],"study_design_scores_gemma":[0.3890829,0.57629,0.01114062,0.0000454713,0.0004211929,0.0004885359,0.00005292607,0.002010964,0.01568093,0.0002018428,0.004529366,0.00005523168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873403,0.001304292,0.0007710013,0.0007257836,0.0001137724,0.003466211,0.0029726,0.000257835,0.00304817],"genre_scores_gemma":[0.9747612,0.001416537,0.003562063,0.001536607,0.00015034,0.003385607,0.008398139,0.00008813693,0.006701304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006603996,"threshold_uncertainty_score":0.02209252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04784817292924273,"score_gpt":0.4463178778974823,"score_spread":0.3984697049682396,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}